The revolutionary impact of immune checkpoint inhibitors (ICIs) has transformed cancer care, yielding unprecedented durable responses across a spectru
Read Full Article To Earn PointsDaily news to keep you up to date
Participate and win exciting prizes
Participate and win cash vouchers
Get updates on the latest events happening around the world
1.
Using AI, one can find cancer risk factors.
2.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
3.
FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC
4.
Does pollution cause cancer?
5.
Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.
1.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
2.
CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review
3.
Cancer Vaccines in Solid Tumors: Current Landscape, Mechanisms, and Clinical Implications
4.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
5.
Unveiling the Hidden Benefits of Lymphedema Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation